. 2024 Mar 18;14:1334846. doi: 10.3389/fonc.2024.1334846

Table 6.

Associations between NUDT15 genotype and risk of severe adverse events and therapy interruption in 92 pediatric acute lymphoblastic leukemia cases.

		NUDT15 genotype
		CC (n=86) N (%)	CT & TT (n=6) N (%)	P-value*	OR*	95%CI
Leukopenia G3/4	No	49 (57)	0 (0)	0.999	>99.00	<0.01–>99.00
Leukopenia G3/4	Yes	37 (43)	6 (100)	0.999	>99.00	<0.01–>99.00
Early onset leukopenia	No	74 (86)	3 (50)	0.037	6.16	1.11-34.18
Early onset leukopenia	Yes	12 (14)	3 (50)	0.037	6.16	1.11-34.18
Thrombocytopenia G3/4	No	80 (93)	6 (100)	0.999	<0.01	<0.01–>99.00
Thrombocytopenia G3/4	Yes	6 (7)	0 (0)	0.999	<0.01	<0.01–>99.00
AST/ALT G3/4	No	75 (87.2)	5 (83.3)	0.786	1.36	0.14-12.78
AST/ALT G3/4	Yes	11 (12.8)	1 (16.7)	0.786	1.36	0.14-12.78
Anemia G3/4	No	81 (94.2)	6 (100)	0.999	<0.01	<0.01–>99.00
Anemia G3/4	Yes	5 (5.8)	0 (0)	0.999	<0.01	<0.01–>99.00
Adverse events G3/4	No	46 (53.5)	0 (0)	0.999	>99.00	<0.01–>99.00
Adverse events G3/4	Yes	40 (46.5)	6 (100)	0.999	>99.00	<0.01–>99.00
Therapy interruption	No	61 (70.9)	4 (66.7)	0.999	<0.01	<0.01–>99.00
Therapy interruption	Yes	25 (29.1)	2 (33.3)	0.999	<0.01	<0.01–>99.00

*Odds ratios and 95% confidence intervals were calculated using logistic regression.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; NUDT15, nucleoside diphosphate-linked moiety X-type motif 15; OR: odds ratio.The bold values indicate statistical significance (P<0.05).